肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Cancer Biomark：Circ0001429通过结合miR-205-5p和促进VEGFA表达来调节膀胱癌的进展

2019-03-27 不详 网络

关注

本研究探讨了circ0001429，miR-205-5p和血管内皮生长因子（VEGFA）在膀胱癌组织中的表达及其对增殖，迁移和凋亡的影响。Arraystar Human CircRNA芯片用于分析四种膀胱癌组织和成对的正常膀胱组织中circRNA的差异表达。利用实时定量PCR检测组织样本中circ0001429的表达。生物信息学，RNA免疫沉淀和荧光素酶报告基因用于验证膀胱癌中circ000142

本研究探讨了circ0001429，miR-205-5p和血管内皮生长因子（VEGFA）在膀胱癌组织中的表达及其对增殖，迁移和凋亡的影响。

Arraystar Human CircRNA芯片用于分析四种膀胱癌组织和成对的正常膀胱组织中circRNA的差异表达。利用实时定量PCR检测组织样本中circ0001429的表达。生物信息学，RNA免疫沉淀和荧光素酶报告基因用于验证膀胱癌中circ0001429，miR-205-5p和VEGFA之间的关系。通过CCK8测定确定细胞增殖，并用transwell迁移测定验证circ0001429和miR-205-5p在细胞迁移中的作用。流式细胞仪和TUNEL染色观察细胞凋亡能力的影响。还进行异种移植实验以验证circ0001429对体内肿瘤生长的影响。

结果显示，与邻近正常膀胱组织相比，circ0001429和VEGFA的表达上调，而miR-205-5p表达在膀胱癌组织中下调。Circ0001429在体外增强了T24细胞和5637细胞的增殖和转移能力，但减少了细胞凋亡。体内实验揭示了sh-circ0001429在肿瘤生长和肺转移中的抑制剂作用。 Circ0001429对靶向VEGFA的miR-205-5p进行了鉴定，从而调节了VEGFA的蛋白质水平。同时，miR-205-5p抑制细胞活力和迁移，促进膀胱癌细胞凋亡。Circ0001429可通过miR-205-5p增加VEGFA表达，加速细胞增殖，迁移和侵袭。

总之，该研究结果表明，Circ0001429和VEGFA在膀胱癌中高表达，而miR-205-5p在膀胱癌中低表达。circ0001429可以靶向miR-205-5p来调节VEGFA并促进膀胱癌的发展。

原始出处：

Cao W, Zhao Y, et al., Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression. Cancer Biomark. 2019 Mar 12. doi: 10.3233/CBM-182380.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918597, encodeId=0f0c191859e4f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 09 05:55:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930695, encodeId=d966193069568, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Nov 10 18:55:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368521, encodeId=a2841368521e0, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Mar 29 02:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039915, encodeId=09711039915bf, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Mar 27 14:55:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363630, encodeId=e56836363000, content=大作已经学习，谢谢把经验分享给同好。点赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Wed Mar 27 12:47:39 CST 2019, time=2019-03-27, status=1, ipAttribution=)]
    2020-03-09 sunylz

    #Bio#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1918597, encodeId=0f0c191859e4f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 09 05:55:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930695, encodeId=d966193069568, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Nov 10 18:55:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368521, encodeId=a2841368521e0, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Mar 29 02:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039915, encodeId=09711039915bf, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Mar 27 14:55:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363630, encodeId=e56836363000, content=大作已经学习，谢谢把经验分享给同好。点赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Wed Mar 27 12:47:39 CST 2019, time=2019-03-27, status=1, ipAttribution=)]
    2019-11-10 smallant2002

    #miR#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1918597, encodeId=0f0c191859e4f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 09 05:55:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930695, encodeId=d966193069568, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Nov 10 18:55:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368521, encodeId=a2841368521e0, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Mar 29 02:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039915, encodeId=09711039915bf, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Mar 27 14:55:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363630, encodeId=e56836363000, content=大作已经学习，谢谢把经验分享给同好。点赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Wed Mar 27 12:47:39 CST 2019, time=2019-03-27, status=1, ipAttribution=)]
    2019-03-29 fanweitanzhen

    #VEGF#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1918597, encodeId=0f0c191859e4f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 09 05:55:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930695, encodeId=d966193069568, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Nov 10 18:55:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368521, encodeId=a2841368521e0, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Mar 29 02:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039915, encodeId=09711039915bf, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Mar 27 14:55:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363630, encodeId=e56836363000, content=大作已经学习，谢谢把经验分享给同好。点赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Wed Mar 27 12:47:39 CST 2019, time=2019-03-27, status=1, ipAttribution=)]
    2019-03-27 留走人康

    膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1918597, encodeId=0f0c191859e4f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Mar 09 05:55:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930695, encodeId=d966193069568, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Nov 10 18:55:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368521, encodeId=a2841368521e0, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Mar 29 02:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039915, encodeId=09711039915bf, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Mar 27 14:55:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363630, encodeId=e56836363000, content=大作已经学习，谢谢把经验分享给同好。点赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Wed Mar 27 12:47:39 CST 2019, time=2019-03-27, status=1, ipAttribution=)]
    2019-03-27 lietome15

    大作已经学习，谢谢把经验分享给同好。点赞了！

    0